Gilead goes long-acting in HIV

Gilead goes long-acting in HIV

Source: 
EP Vantage
snippet: 

Gilead has finally got the FDA's nod for its novel HIV therapy, the long-acting capsid inhibitor lenacapavir, after previous issues with the vials in which the drug had been stored. The approval is in patients with multidrug-resistant HIV, who account for around 2% of the total HIV population, the company estimates.